Compare · ARAY vs WST
ARAY vs WST
Side-by-side comparison of Accuray Incorporated (ARAY) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARAY and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $21.24B, about 383.2x ARAY ($55.4M).
- Over the past year, ARAY is down 65.4% and WST is up 42.9% - WST leads by 108.4 points.
- ARAY has been more active in the news (8 items in the past 4 weeks vs 7 for WST).
- WST has more recent analyst coverage (15 ratings vs 3 for ARAY).
- Company
- Accuray Incorporated
- West Pharmaceutical Services Inc.
- Price
- $0.47+0.71%
- $300.70+1.05%
- Market cap
- $55.4M
- $21.24B
- 1M return
- +19.77%
- +18.93%
- 1Y return
- -65.44%
- +42.93%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2007
- News (4w)
- 8
- 7
- Recent ratings
- 3
- 15
Accuray Incorporated
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest ARAY
- Accuray Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
- Amendment: SEC Form SCHEDULE 13D/A filed by Accuray Incorporated
- SEC Form 3 filed by new insider Tcw Group Inc
- SEC Form 3 filed by new insider Miele Paul Michael
- Accuray Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Accuray Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
- SEC Form 4 filed by Chalke Sandeep
- Amendment: SEC Form SCHEDULE 13G/A filed by Accuray Incorporated
Latest WST
- Sr. VP & Chief HR Officer Favorite Annette F exercised 2,817 shares at a strike of $83.47 and sold $859,753 worth of shares (2,817 units at $305.20) (SEC Form 4)
- VP, Chief Accounting Officer Winters Chad exercised 896 shares at a strike of $173.22 and sold $269,399 worth of shares (896 units at $300.67) (SEC Form 4)
- West to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Reports First-Quarter 2026 Results
- West to Host First-Quarter 2026 Conference Call
- SEC Form 4 filed by Haugen Janet Brutschea
- West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.